B/HPIV3/S-6P
/ National Institute of Allergy and Infectious Diseases, Johns Hopkins Bloomberg School of Public Health
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
July 10, 2024
Phase I Safety Study of B/HPIV3/S-6P Vaccine Via Nasal Spray in Adults
(clinicaltrials.gov)
- P1 | N=27 | Active, not recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting ➔ Active, not recruiting
Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
September 07, 2023
Phase I Safety Study of B/HPIV3/S-6P Vaccine Via Nasal Spray in Adults
(clinicaltrials.gov)
- P1 | N=30 | Recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
1 to 2
Of
2
Go to page
1